PubMed=35628345; DOI=10.3390/ijms23105535
Goto N., Suzuki H., Tanaka T., Asano T., Kaneko M.K., Kato Y.
Development of a novel anti-CD44 monoclonal antibody for multiple applications against esophageal squamous cell carcinomas.
Int. J. Mol. Sci. 23:5535.1-5535.15(2022)

PubMed=36835416; DOI=10.3390/ijms24044007
Ejima R., Suzuki H., Tanaka T., Asano T., Kaneko M.K., Kato Y.
Development of a novel anti-CD44 variant 6 monoclonal antibody C44Mab-9 for multiple applications against colorectal carcinomas.
Int. J. Mol. Sci. 24:4007.1-4007.16(2023)

PubMed=36975491; DOI=10.3390/cimb45030121
Suzuki H., Tanaka T., Goto N., Kaneko M.K., Kato Y.
Development of a novel anti-CD44 variant 4 monoclonal antibody C44Mab-108 for immunohistochemistry.
Curr. Issues Mol. Biol. 45:1875-1888(2023)

PubMed=37176118; DOI=10.3390/ijms24098411
Suzuki H., Kitamura K., Goto N., Ishikawa K., Ouchida T., Tanaka T., Kaneko M.K., Kato Y.
A novel anti-CD44 variant 3 monoclonal antibody C44Mab-6 was established for multiple applications.
Int. J. Mol. Sci. 24:8411.1-8411.17(2023)

PubMed=37185762; DOI=10.3390/cimb45040238
Tawara M., Suzuki H., Goto N., Tanaka T., Kaneko M.K., Kato Y.
A novel anti-CD44 variant 9 monoclonal antibody C44Mab-1 Was developed for immunohistochemical analyses against colorectal cancers.
Curr. Issues Mol. Biol. 45:3658-3673(2023)

PubMed=37218897; DOI=10.3390/antib12020031
Kudo Y., Suzuki H., Tanaka T., Kaneko M.K., Kato Y.
Development of a novel anti-CD44 variant 5 monoclonal antibody C44Mab-3 for multiple applications against pancreatic carcinomas.
Antibodies 12:31.1-31.16(2023)

PubMed=37504249; DOI=10.3390/cimb45070333
Ishikawa K., Suzuki H., Kaneko M.K., Kato Y.
Establishment of a novel anti-CD44 variant 10 monoclonal antibody C44Mab-18 for immunohistochemical analysis against oral squamous cell carcinomas.
Curr. Issues Mol. Biol. 45:5248-5262(2023)